Update On Vyvanse (lisdexamfetamine Dimesilate) Investigation
Vyvanse Investigation Summary The FDA investigated concerns about whether Vyvanse (lisdexamfetamine dimesilate) was working properly and met quality and safety standards. The investigation found no problems with the medication's effectiveness, quality, or safety. This is a Class II notification affecting Vyvanse distributed throughout Australia.
- Reason
- Our investigation into concerns about Vyvanse’s potential lack of effectiveness, quality and safety found no issues of concern.
- Classification
- Class II
- Category
- drug recall
- Country
- Australia
- Agency
- Therapeutic Goods Administration
- Recall date
- 2025-09-26
- Status
- Ongoing
- Distribution
- Australia-wide
Official recall notice from Therapeutic Goods Administration
Recall details on Nibble Recalls: https://trynibble.app/recalls/7bde1fe5-3b0b-428b-b851-acaf7e32e9f6